Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tonix Pharma (TNXP)
NASDAQ:TNXP
Holding TNXP?
Track your performance easily
TNXP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.12 - $12.50
Previous CloseN/A
Volume36.66M
Average Volume (3M)173.85M
Market Cap
$43.92M
Enterprise Value-$10.32M
Total Cash (Recent Filing)$26.12M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 17, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.56
Shares Outstanding186,894,230
10 Day Avg. Volume67,367,022
30 Day Avg. Volume173,847,559
Standard Deviation0.40
R-Squared0.07
Alpha-0.11
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.85
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.23
Enterprise Value/Revenue-0.90
Enterprise Value/Gross Profit-3.41
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$4.00Price Target Upside1566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Tonix Pharma News
PremiumMarket News
3 Penny Stocks to Watch Now, 12/24/24
PremiumCompany Announcements
Tonix Pharma Announces Key Appointment and Study Timelines
PremiumCompany Announcements
Tonix Pharma Awaits FDA Decision on TNX-102 SL
PremiumMarket News
3 Penny Stocks to Watch Now, 12/19/24
PremiumCompany Announcements
Tonix Pharma’s TNX-102 SL Nears FDA Approval MilestoneOwnership Overview
0.07%
Insiders
0.01% Mutual Funds
0.04% Other Institutional Investors
99.88% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TNXP FAQ
What was Tonix Pharma’s price range in the past 12 months?
Tonix Pharma lowest stock price was $0.12 and its highest was $12.50 in the past 12 months.
What is Tonix Pharma’s market cap?
Tonix Pharma’s market cap is $43.92M.
When is Tonix Pharma’s upcoming earnings report date?
Tonix Pharma’s upcoming earnings report date is Mar 17, 2025 which is in 58 days.
How were Tonix Pharma’s earnings last quarter?
Tonix Pharma released its earnings results on Nov 12, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$3.88 by $3.65.
Is Tonix Pharma overvalued?
According to Wall Street analysts Tonix Pharma’s price is currently Undervalued.
Does Tonix Pharma pay dividends?
Tonix Pharma does not currently pay dividends.
What is Tonix Pharma’s EPS estimate?
Tonix Pharma’s EPS estimate is -0.19.
How many shares outstanding does Tonix Pharma have?
Tonix Pharma has 186,894,230 shares outstanding.
What happened to Tonix Pharma’s price movement after its last earnings report?
Tonix Pharma reported an EPS of -$0.23 in its last earnings report, beating expectations of -$3.88. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tonix Pharma?
Currently, no hedge funds are holding shares in TNXP
---
Tonix Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (1566.67% Upside)
$4.00 (1566.67% Upside)
Blogger Sentiment
Bullish
TNXP Sentiment 66%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 34.5%
Last 30 Days ▲ 34.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-97.62%
12-Months-Change
Fundamentals
Return on Equity
-138.69%
Trailing 12-Months
Asset Growth
-31.80%
Trailing 12-Months
Company Description
Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.
---
TNXP Stock 12 Month Forecast
Average Price Target
$4.00
▲(1566.67% Upside)
Technical Analysis
Aptorum Group
―
Genprex
―
TuHURA Biosciences
―
Leap Therapeutics
―
PAVmed
―
Assembly Biosciences
―
Best Analysts Covering TNXP
1 Year
1 Year Success Rate
1/18 ratings generated profit
1 Year Average Return
-73.72%
reiterated a buy rating last month
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 5.56% of your transactions generating a profit, with an average return of -73.72% per trade.
---